Moderna, Inc.
545 articles with Moderna, Inc.
-
U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine
6/16/2021
Moderna, Inc., (Nasdaq: MRNA) today announced that the U.S. government has purchased an additional 200 million doses of Moderna’s COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.
-
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates
6/15/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Magenta Investments, a leading pharmaceutical and healthcare company that is part of an investment and industrial conglomerate in the United Arab Emirates (UAE), today announced a new agreement to distribute the Moderna COVID-19 Vaccine
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland
6/14/2021
Moderna, Inc. today announced that it has submitted an authorization application to Swissmedic for use of its COVID-19 vaccine in adolescents.
-
Dr. Paul Burton to Join Moderna as Chief Medical Officer
6/14/2021
Moderna , Inc., today announced that Paul Burton, M.D., Ph.D., F.A.C.C, M.R.C.S will join the Company as Chief Medical Officer, effective July 6, 2021.
-
Flagship Pioneering announced a massive cash infusion to support the development and launch of new companies aiming at various diseases and global health threats.
-
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
-
Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia
6/11/2021
Moderna, Inc. and Tabuk Pharmaceutical Manufacturing Company today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.
-
According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.
-
Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States
6/10/2021
Moderna, Inc. today announced that it has requested an emergency use authorization (EUA) for its COVID-19 vaccine in adolescents with the U.S. Food and Drug Administration (FDA).
-
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
-
Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents
6/7/2021
Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for authorization of its COVID-19 vaccine in adolescents with Health Canada.
-
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
6/7/2021
Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted for a conditional marketing approval (CMA) for its COVID-19 vaccine in adolescents with the European Medicines Agency (EMA).
-
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
6/7/2021
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
-
Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
6/3/2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the Government of the Republic of Botswana for Moderna’s vaccine against COVID-19, to support the government’s ongoing efforts to secure access to a COVID-19 vaccines for the people of Botswana
-
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
6/2/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and UNICEF announced that they have signed a long-term agreement for the supply of COVID-19 vaccine on behalf of the COVAX Facility as part of the agreement announced in May 2021.
-
Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands
6/2/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that it has entered into an additional agreement with Lonza to support drug substance manufacturing for its global supply chain.
-
A flurry of COVID-19 research news came out today. Here’s a look.
-
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
6/1/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older.
-
Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
6/1/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID-19 vaccine